Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patientsShow others and affiliations
2023 (English)In: Clinical Kidney Journal, ISSN 2048-8505, E-ISSN 2048-8513, Vol. 16, no 12, p. 2378-2392Article, review/survey (Refereed) Published
Abstract [en]
There is growing evidence that chronic kidney disease (CKD) is an independent risk factor for cognitive impairment, especially due to vascular damage, blood-brain barrier disruption and uremic toxins. Given the presence of multiple comorbidities, the medication regimen of CKD patients often becomes very complex. Several medications such as psychotropic agents, drugs with anticholinergic properties, GABAergic drugs, opioids, corticosteroids, antibiotics and others have been linked to negative effects on cognition. These drugs are frequently included in the treatment regimen of CKD patients. The first review of this series described how CKD could represent a risk factor for adverse drug reactions affecting the central nervous system. This second review will describe some of the most common medications associated with cognitive impairment (in the general population and in CKD) and describe their effects. Graphical Abstract
Place, publisher, year, edition, pages
OXFORD UNIV PRESS , 2023. Vol. 16, no 12, p. 2378-2392
Keywords [en]
adverse drug reaction; chronic kidney disease; cognitive impairment; drug prescription; medications
National Category
Urology and Nephrology
Identifiers
URN: urn:nbn:se:liu:diva-198864DOI: 10.1093/ckj/sfad239ISI: 001081414700001OAI: oai:DiVA.org:liu-198864DiVA, id: diva2:1808959
Note
Funding Agencies|The authors would like to thank Prof. Giovambattista Capasso, acting chair of Cognitive Decline in Nephro-Neurology: European Cooperative Target (CONNECT) Action and members of COST Action for their support.
2023-11-012023-11-012024-05-03